Répertoire du corps professoral

Is treatment with a combination of licensed influenza antivirals superior to monotherapy for highly pathogenic H5N1 influenza virus from cattle?
Programme: Subvention catalyseur : Recherche « Une seule santé » sur la grippe aviaire
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 septembre 2024 au 31 août 2025

Fond de démarrage-Nouveau chercheur
Organisme(s) subventionnaire(s): Fondation du CHU de Québec, CHU de Québec – Université Laval – CHUL
Type de financement: Subvention
Établissement tête: Université Laval
Du 27 mai 2024 au 31 mars 2027

Chaire d’excellence de recherche du Canada on Biology and Control of Zoonotic and Pandemic Respiratory Viruses
Programme: Programme de chaires d'excellence en recherche du Canada
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 septembre 2023 au 26 mai 2033

Aerosol Infection Research: Better mOdels to Reduce iNdoor Exposure (AIRBORNE)
Programme: 2021 Coronavirus Research Response – Covid-19 Treatment Access and Public Health Activities
Organisme(s) subventionnaire(s): Medical Research Future Fund
Type de financement: Subvention
Établissement tête: The University of Melbourne
Du 1 juin 2022 au 30 mai 2025

Publications des 5 dernières années

Implications of the apparent extinction of B/Yamagata-lineage human influenza viruses npj Vaccines, 2024/11/16. Ian G. Barr, Kanta Subbarao. DOI 10.1038/s41541-024-01010-y

Role of the viral polymerase during adaptation of influenza A viruses to new hosts Current Opinion in Virology, 2023/10. Brad Gilbertson, Melanie Duncan, Kanta Subbarao. DOI 10.1016/j.coviro.2023.101363

Mammalian infections with highly pathogenic avian influenza viruses renew concerns of pandemic potential Journal of Experimental Medicine, 2023/08/07. Brad Gilbertson, Kanta Subbarao. DOI 10.1084/jem.20230447

Comparative Longitudinal Serological Study of Anti-SARS-CoV-2 Antibody Profiles in People with COVID-19 Microorganisms, 2023/08. Marilou H. Barrios, Suellen Nicholson, Rowena Bull, Marianne Martinello, William Rawlinson, Michael MIna, Jeffrey J. Post, Bernard Hudson, Nicole Gilroy, Andrew Lloyd, Pamela Konecny, Francesca Mordant, Mike Catton, Kanta Subbarao, Leon Caly, Julian Druce, Hans Juergen Netter. DOI 10.3390/microorganisms11081985

Predicting the efficacy of variant-modified COVID-19 vaccine boosters Nature Medicine, 2023/03. David S. Khoury, Steffen S. Docken, Kanta Subbarao, Stephen J. Kent, Miles P. Davenport, Deborah Cromer. DOI 10.1038/s41591-023-02228-4

Sequential Transmission of Influenza Viruses in Ferrets Does Not Enhance Infectivity and Does Not Predict Transmissibility in Humans mBio, 2022/12/20. Troy C. Sutton, Elaine W. Lamirande, Devanshi R. Patel, Katherine E. E. Johnson, Rita Czako, Elodie Ghedin, Raphael T. C. Lee, Sebastian Maurer-Stroh, Kanta Subbarao. DOI 10.1128/mbio.02540-22

Heparin Inhibits SARS-CoV-2 Replication in Human Nasal Epithelial Cells Viruses, 2022/11. Leo Yi Yang Lee, Randy Suryadinata, Conor McCafferty, Vera Ignjatovic, Damian Purcell, Phil Robinson, Craig Morton, Michael W. Parker, Gary P. Anderson, Paul Monagle, Kanta Subbarao, Jessica. DOI 10.3390/v14122620

A new route to vaccines using PROTACs Nature Biotechnology, 2022/09. Brad Gilbertson, Kanta Subbarao. DOI 10.1038/s41587-022-01406-y

Correlates of protection, thresholds of protection, and immunobridging in SARS-CoV-2 infection 2022/06/06. David S Khoury, Timothy E Schlub, Deborah Cromer, Megan Steain, Youyi Fong, Peter B Gilbert, Kanta Subbarao, James A Triccas, Stephen J Kent, Miles P Davenport. DOI 10.1101/2022.06.05.22275943

What influenza activity can we anticipate in 2022? Medical Journal of Australia, 2022/03/21. Kanta Subbarao. DOI 10.5694/mja2.51437

Opposing Effects of Prior Infection versus Prior Vaccination on Vaccine Immunogenicity against Influenza A(H3N2) Viruses Viruses, 2022/02/25. Annette Fox, Louise Carolan, Vivian Leung, Hoang Vu Mai Phuong, Arseniy Khvorov, Maria Auladell, Yeu-Yang Tseng, Pham Quang Thai, Ian Barr, Kanta Subbarao, Le Thi Quynh Mai, H. Rogier van Doorn, Sheena G. Sullivan. DOI 10.3390/v14030470

Off‐target effects of bacillus Calmette–Guérin vaccination on immune responses to SARS‐CoV‐2: implications for protection against severe COVID‐19 Clinical & Translational Immunology, 2022/01. Nicole L Messina, Susie Germano, Rebecca McElroy, Rajeev Rudraraju, Rhian Bonnici, Laure F Pittet, Melanie R Neeland, Suellen Nicholson, Kanta Subbarao, Nigel Curtis. DOI 10.1002/cti2.1387

Long-read RNA sequencing identifies polyadenylation elongation and differential transcript usage of host transcripts during SARS-CoV-2 in vitro infection 2021/12/15. Jessie J.-Y. Chang, Josie Gleeson, Daniel Rawlinson, Miranda E. Pitt, Ricardo De Paoli-Iseppi, Chenxi Zhou, Francesca L. Mordant, Sarah L. Londrigan, Michael B. Clark, Kanta Subbarao, Timothy P. Stinear, Lachlan J.M. Coin. DOI 10.1101/2021.12.14.472725

A second external quality assessment of isolation and identification of influenza viruses in cell culture in the Asia Pacific region highlights improved performance by participating laboratories Journal of Clinical Virology, 2021/09. Vivian K.Y. Leung, Yi-Mo Deng, Angela Todd, Heidi Peck, Iwona Buettner, Tasoula Zakis, Kanta Subbarao, Ian G. Barr, Karen Nahapetyan, Francis Y. Inbanathan, Magdi Samaan, Patrick C. Reading. DOI 10.1016/j.jcv.2021.104907

Prevalence of Neutralising Antibodies to HCoV-NL63 in Healthy Adults in Australia Viruses, 2021/08/16. Sean A. Lynch, Kanta Subbarao, Siddhartha Mahanty, Bridget E. Barber, Eileen V. Roulis, Lia van der Hoek, James S. McCarthy, Kirsten M. Spann. DOI 10.3390/v13081618

What level of neutralising antibody protects from COVID-19? 2021/03/11. David S Khoury, Deborah Cromer, Arnold Reynaldi, Timothy E Schlub, Adam K Wheatley, Jennifer A Juno, Kanta Subbarao, Stephen J Kent, James A Triccas, Miles P Davenport. DOI 10.1101/2021.03.09.21252641

Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques Nature Communications, 2021/03/03. Hyon-Xhi Tan, Jennifer A. Juno, Wen Shi Lee, Isaac Barber-Axthelm, Hannah G. Kelly, Kathleen M. Wragg, Robyn Esterbauer, Thakshila Amarasena, Francesca L. Mordant, Kanta Subbarao, Stephen J. Kent, Adam K. Wheatley. DOI 10.1038/s41467-021-21665-8

Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models Nature Reviews Immunology, 2020/12/02. David S. Khoury, Adam K. Wheatley, Mitchell D. Ramuta, Arnold Reynaldi, Deborah Cromer, Kanta Subbarao, David H. O’Connor, Stephen J. Kent, Miles P. Davenport. DOI 10.1038/s41577-020-00471-1

Convalescent plasma treatment for COVID‐19: Tempering expectations with the influenza experience European Journal of Immunology, 2020/10. Kanta Subbarao, Francesca Mordant, Rajeev Rudraraju. DOI 10.1002/eji.202048723

Live Attenuated Influenza Vaccines for Pandemic Preparedness Journal of the Pediatric Infectious Diseases Society, 2020/03/19. Kanta Subbarao. DOI 10.1093/jpids/piz073

The Critical Interspecies Transmission Barrier at the Animal–Human Interface Tropical Medicine and Infectious Disease, 2019/04/25. Kanta Subbarao. DOI 10.3390/tropicalmed4020072

Immune Responses to Avian Influenza Viruses The Journal of Immunology, 2019/01/15. Marios Koutsakos, Katherine Kedzierska, Kanta Subbarao. DOI 10.4049/jimmunol.1801070